GlassScriptPhysician profile
Kimberly Rogers
NPI 1053300665
$4,744.84
in general payments reported to CMS, 2019-2025
33 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $840 · 2022: $668 · 2023: $954 · 2024: $1,244 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,237.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $754.33 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $753.52 | 2021-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $498.29 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $479.53 | 2021-2025 | Rybelsus, Ozempic |
| Insulet Corporation | $278.67 | 2022-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $240.16 | 2021-2024 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $219.44 | 2024-2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.94 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Sanofi-Aventis U.S. LLC | $181.26 | 2021-2023 | |
| Horizon Therapeutics Plc | $173.29 | 2023 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $147.49 | 2024-2025 | Farxiga, Fasenra |
| Alexion Pharmaceuticals, INC. | $112.68 | 2023-2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $75.19 | 2022-2024 | |
| Beta Bionics, INC. | $74.71 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $64.45 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $61.82 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $41.06 | 2021-2024 | Minimed 780g |
| Sequel Med Tech, LLC | $40.20 | 2025 | Twiist |
| Exact Sciences Corporation | $35.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $34.75 | 2021 | |
| 3b Medical, INC. | $29.74 | 2025 | Luna |
| Astellas Pharma US INC | $29.27 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $27.24 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.26 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $23.85 | 2024 | Imcivree |
| Verona Pharma, INC. | $23.22 | 2025 | Ohtuvayre |
| Ultragenyx Pharmaceutical INC. | $22.33 | 2021 | |
| Cequr Corporation | $21.84 | 2024 | Cequr Simplicity |
| Abbvie INC. | $20.68 | 2022 | |
| Ibsa Pharma INC. | $17.67 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.02 | 2025 | Dupixent |
| Soleno Therapeutics, INC. | $15.94 | 2025 | Vykat Xr |
| Lifescan, INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.